It is a chimeric (hybrid) monoclonal antibody.
Mechanism of action:
In this hybrid monoclonal antibody i.e. constant regions of human immunoglobulin and Fab fragments of murine monoclonal antibody gets bind to platelet GP IIb/IIIa receptos leading to blockage of the binding of fibrinogen and von Willebrand factor resulting in inhibition of aggregation.
It is administered intravenously with aspirin and heparin.
Note: After stoppage of therapy platelet function gradually returns to normal.
It is used for the prevention of cardiac ischemia.
It is also recommended for patients with unstable angina.
It may cause bleeding disorders. Thrombocytopenia may also be caused.